Patient characteristics
| Characteristics . | n . | % . |
|---|---|---|
| Number of patients | 990 | |
| Recipient age, median (range), y | 53.5 (17-75) | |
| Donor age, median (range), y | 37 (14-71) | |
| Sex, M/F | 432/558 | 44/56 |
| Disease | ||
| Lymphoid | 406 | 41 |
| Acute lymphoblastic leukemia | 115 | 12 |
| CLL and prolymphocytic leukemia | 23 | 2 |
| HL | 108 | 11 |
| NHL | 127 | 13 |
| Multiple myeloma | 33 | 3 |
| Myeloid | 584 | 59 |
| Aplastic anemia | 2 | 0.2 |
| Acute myeloid leukemia | 391 | 39 |
| CML | 26 | 3 |
| CMML | 9 | 1 |
| MDS | 102 | 10 |
| Myelofibrosis | 44 | 5 |
| Other myeloproliferative disease | 10 | 0.8 |
| Disease status pre–allogeneic SCT | ||
| CR | 550 | 56 |
| PR | 93 | 9 |
| SD/PD | 347 | 35 |
| DRI (N = 956) | ||
| Low-Int | 603 | 63 |
| High-VH | 353 | 37 |
| Conditioning regimens | ||
| NMA | 635 | 64 |
| TBI-Cy-fludarabine ± thiotepa | 265 | 27 |
| Busulfan-fludarabine ± thiotepa | 322 | 33 |
| Thiotepa-Cy ± melphalan or ± fludarabine | 25 | 2 |
| Sequential (with clofarabine) | 23 | 2 |
| Myeloablative | 355 | 36 |
| Thiotepa-fludarabine-busulfan | 246 | 25 |
| TBI based (± Cy or fludarabine) | 76 | 8 |
| Others | 33 | 3 |
| GVHD prophylaxis | ||
| Classical PT-Cy | 620 | 63 |
| Modified PT-Cy | 370 | 37 |
| CMV serostatus (N = 976) | ||
| Neg/Neg | 120 | 12 |
| Pos/Neg | 92 | 10 |
| Pos/Pos | 549 | 56 |
| Neg/Pos | 212 | 22 |
| Other with recipient Pos | 3 | 0 |
| HCT-CI (N = 973) | ||
| 0-1 | 449 | 46 |
| 2 | 162 | 17 |
| ≥3 | 362 | 37 |
| Sex mismatch (N = 989) | ||
| No F→M | 754 | 76 |
| F→M | 235 | 24 |
| Graft source | ||
| BM | 617 | 62 |
| PBSC | 373 | 38 |
| Donor/recipient relationship (N = 987) | ||
| Child | 468 | 47 |
| Sibling | 344 | 35 |
| Parent | 144 | 15 |
| Other | 31 | 3 |
| Characteristics . | n . | % . |
|---|---|---|
| Number of patients | 990 | |
| Recipient age, median (range), y | 53.5 (17-75) | |
| Donor age, median (range), y | 37 (14-71) | |
| Sex, M/F | 432/558 | 44/56 |
| Disease | ||
| Lymphoid | 406 | 41 |
| Acute lymphoblastic leukemia | 115 | 12 |
| CLL and prolymphocytic leukemia | 23 | 2 |
| HL | 108 | 11 |
| NHL | 127 | 13 |
| Multiple myeloma | 33 | 3 |
| Myeloid | 584 | 59 |
| Aplastic anemia | 2 | 0.2 |
| Acute myeloid leukemia | 391 | 39 |
| CML | 26 | 3 |
| CMML | 9 | 1 |
| MDS | 102 | 10 |
| Myelofibrosis | 44 | 5 |
| Other myeloproliferative disease | 10 | 0.8 |
| Disease status pre–allogeneic SCT | ||
| CR | 550 | 56 |
| PR | 93 | 9 |
| SD/PD | 347 | 35 |
| DRI (N = 956) | ||
| Low-Int | 603 | 63 |
| High-VH | 353 | 37 |
| Conditioning regimens | ||
| NMA | 635 | 64 |
| TBI-Cy-fludarabine ± thiotepa | 265 | 27 |
| Busulfan-fludarabine ± thiotepa | 322 | 33 |
| Thiotepa-Cy ± melphalan or ± fludarabine | 25 | 2 |
| Sequential (with clofarabine) | 23 | 2 |
| Myeloablative | 355 | 36 |
| Thiotepa-fludarabine-busulfan | 246 | 25 |
| TBI based (± Cy or fludarabine) | 76 | 8 |
| Others | 33 | 3 |
| GVHD prophylaxis | ||
| Classical PT-Cy | 620 | 63 |
| Modified PT-Cy | 370 | 37 |
| CMV serostatus (N = 976) | ||
| Neg/Neg | 120 | 12 |
| Pos/Neg | 92 | 10 |
| Pos/Pos | 549 | 56 |
| Neg/Pos | 212 | 22 |
| Other with recipient Pos | 3 | 0 |
| HCT-CI (N = 973) | ||
| 0-1 | 449 | 46 |
| 2 | 162 | 17 |
| ≥3 | 362 | 37 |
| Sex mismatch (N = 989) | ||
| No F→M | 754 | 76 |
| F→M | 235 | 24 |
| Graft source | ||
| BM | 617 | 62 |
| PBSC | 373 | 38 |
| Donor/recipient relationship (N = 987) | ||
| Child | 468 | 47 |
| Sibling | 344 | 35 |
| Parent | 144 | 15 |
| Other | 31 | 3 |
TBI, 2 or 12 Gy.
CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia, CMML: chronic myelomonocytic leukemia; CR, complete remission; Cy, cyclophosphamide; DRI, disease risk index; F, female; F→M, female donor into male recipient; HL, Hodgkin lymphoma; Low-Int, low-intermediate; M, male; MDS, myelodysplastic syndrome; Neg, negative; NHL, non-Hodgkin lymphoma; Pos, positive; PR, partial remission; SD/PD, stable/progressive disease; VH, very high.